🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Sanjay Popat

Royal Marsden NHS Foundation Trust

ORCID: 0000-0003-2087-4963

Also affiliated with Institute of Cancer Research, Inserm, Université de Lille, Cancer Research UK, Centre Hospitalier Universitaire de Lille, Institute of Cancer Research, Sutton Hospital, Royal Marsden Hospital, Centre de Recherche en Cancérologie de Lyon, Onco Lille, CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers, Imperial College London

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 6 papers. Top paper: “First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743”.

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Annals of Oncology(2022)10.1016/j.annonc.2022.01.074

N/A

5.7DataRank · unranked

265 citations

Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma +15 more

Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

Cell Reports Medicine(2022)10.1016/j.xcrm.2022.100781

N/A

1.1DataRank · unranked

26 citations

Scott T.C. Shepherd, Lewis Au, Mary Wu, Ruth Harvey, Katalin A. Wilkinson +59 more

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

Cancer Cell(2023)10.1016/j.ccell.2023.04.005

N/A

0.770DataRank · unranked

10 citations

Scott T.C. Shepherd, Annika Fendler, Edward J Carr, Lewis Au, Ruth Harvey +61 more

ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

Lung Cancer(2025)10.1016/j.lungcan.2025.108635

N/A

0.345DataRank · unranked

9 citations

Georgia Dimopoulou, Paul van Schil, David König, Laetitia Mauti, Malinda Itchins +17 more

A tailored approach to horizon scanning for cancer medicines

Journal of Cancer Policy(2023)10.1016/j.jcpo.2023.100441

N/A

0.241DataRank · unranked

4 citations

Yat Hang To, Marliese Alexander, Karen Trapani, Paolo A. Ascierto, Sophy Athan +28 more

7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology(2025)10.1016/s1556-0864(25)00202-3

N/A

0DataRank · unranked

7 citations

Achim Rittmeyer, F. de Marinis, D.H. Lee, S. Gadgeel, Noelia Vilariño +11 more